Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

ANGLE plc

Healthcare GB AGL

1.175GBX
-1.225(51.04%)

Last update at 2025-11-26T08:00:00Z

Day Range

1.001.22
LowHigh

52 Week Range

9.0755.00
LowHigh

Fundamentals

  • Previous Close 2.40
  • Market Cap31.53M
  • Volume4760294
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-23.88900M
  • Revenue TTM1.82M
  • Revenue Per Share TTM0.007
  • Gross Profit TTM -0.16300M
  • Diluted EPS TTM-0.09

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2019-04-30
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2019-04-30
Income before tax -24.43900M -17.36300M -13.74500M -7.73000M -10.87100M
Minority interest - - - - -0.01000M
Net income -21.68600M -15.01200M -11.60600M -6.24800M -8.94200M
Selling general administrative 0.56M 0.34M 0.37M 3.50M 0.24M
Selling and marketing expenses - - - - -
Gross profit 0.61M 0.71M 0.60M -0.00600M 0.52M
Reconciled depreciation 2.84M 1.49M 1.00M - 1.07M
Ebit -24.20700M -17.23500M -13.73100M -12.63000M -10.89900M
Ebitda -21.23300M -15.71900M -12.23400M - -9.82500M
Depreciation and amortization 2.97M 1.52M 1.50M - 1.07M
Non operating income net other - - - - -
Operating income -24.20700M -17.23500M -13.73100M -7.70400M -10.89900M
Other operating expenses 25.25M 18.25M 14.49M 1.55M 11.58M
Interest expense 0.37M 0.16M 0.09M 0.00000M 0.02M
Tax provision -2.75300M -2.35100M -2.13900M -1.48200M -1.93900M
Interest income 0.14M 0.03M 0.08M 0.02M 0.03M
Net interest income -0.23200M -0.12800M -0.01400M - 0.03M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -2.75300M -2.35100M -2.13900M -2.22300M -1.93900M
Total revenue 1.04M 1.01M 0.76M 0.58M 0.68M
Total operating expenses 24.82M 17.95M 14.33M - 11.42M
Cost of revenue 0.43M 0.30M 0.17M 0.59M 0.15M
Total other income expense net -0.23200M -0.12800M -0.01400M - 0.03M
Discontinued operations - - - - -
Net income from continuing ops -21.68600M -15.01200M -11.60600M - -8.93200M
Net income applicable to common shares -21.68600M -15.01200M -11.60600M -11.33400M -8.94200M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2019-04-30
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2019-04-30
Total assets 49.87M 47.31M 39.05M 34.30M 23.02M
Intangible assets 0.56M 1.37M 1.50M 5.49M 6.83M
Earning assets - - - - -
Other current assets - 5.78M 3.57M - 2.84M
Total liab 9.80M 6.99M 4.71M 3.98M 3.68M
Total stockholder equity 40.06M 40.33M 34.34M 30.32M 19.34M
Deferred long term liab 0.03M 0.04M 0.12M 0.21M 3.00M
Other current liab 0.61M 1.04M 1.86M 0.32M 1.90M
Common stock 26.06M 23.51M 21.54M 17.28M 14.35M
Capital stock 26.06M 23.51M 21.54M - 14.35M
Retained earnings -103.70200M -83.80800M -69.13900M -57.57400M -51.64100M
Other liab 0.22M 0.26M - - -
Good will 2.21M 2.21M 2.21M 2.21M 2.21M
Other assets 0.03M 0.04M 0.12M 0.21M 3.00M
Cash 31.90M 31.84M 12.08M 18.77M 11.01M
Cash and equivalents - - - - -
Total current liabilities 5.25M 4.91M 3.78M 2.78M 3.68M
Current deferred revenue - - - - -
Net debt -26.89500M -29.50100M -10.71800M - -11.01000M
Short term debt 0.66M 0.52M 0.43M - -
Short long term debt - - - - -
Short long term debt total 5.00M 2.34M 1.36M 1.55M -
Other stockholder equity 117.71M 100.62M 81.94M -0.37800M 56.63M
Property plant equipment 8.48M 4.38M 2.41M 3.02M 1.35M
Total current assets 38.63M 39.37M 32.93M 23.58M 14.84M
Long term investments - - - - -
Net tangible assets 37.33M 36.76M 30.75M 22.83M 15.51M
Short term investments - - 16.54M - -
Net receivables 1.80M 1.27M 2.99M 3.70M 2.38M
Long term debt - - - - -
Inventory 2.06M 1.75M 0.74M 0.79M 0.99M
Accounts payable 3.98M 4.39M 3.34M 0.91M 3.68M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -1.46900M
Additional paid in capital - - - - -
Common stock total equity - - 21.54M - 14.35M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - -0.10200M -0.10200M -0.10200M
Accumulated amortization - - - - -
Non currrent assets other - 3.57M - - 8.18M
Deferred long term asset charges - - - - -
Non current assets total 11.24M 7.95M 6.12M - 8.18M
Capital lease obligations 5.00M 2.34M 1.36M - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2019-04-30
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2019-04-30
Investments -1.75100M 14.77M -1.53000M -22.51350M -22.51350M
Change to liabilities -0.97800M 1.42M 0.87M -1.75650M 0.61M
Total cashflows from investing activities -1.75100M 14.77M -1.96600M -23.34600M -1.32400M
Net borrowings -0.81400M -0.61400M -0.46300M -0.34650M -0.34650M
Total cash from financing activities 18.10M 18.99M 18.14M 25.01M 12.00M
Change to operating activities 0.59M 0.59M 0.59M 0.59M -
Net income -24.43900M -17.36300M -13.74500M -11.33400M -10.87100M
Change in cash 0.06M 19.76M 8.32M -10.87950M 3.37M
Begin period cash flow 31.84M 12.08M 3.76M 11.01M 7.64M
End period cash flow 31.90M 31.84M 12.08M 3.76M 11.01M
Total cash from operating activities -16.05000M -14.01000M -7.84800M -12.54900M -7.31400M
Issuance of capital stock 19.05M 19.69M 18.65M - 12.00M
Depreciation 2.84M 1.49M 1.42M 1.16M 1.07M
Other cashflows from investing activities 0.14M 0.02M 0.07M 0.06M 0.03M
Dividends paid - - - - -
Change to inventory -0.58000M -1.01500M 0.01M 0.14M -0.58300M
Change to account receivables -0.65000M 0.20M -0.65800M 0.47M -0.09100M
Sale purchase of stock - - 18.65M 16.92M 12.00M
Other cashflows from financing activities -0.94900M -0.69900M -0.50700M -0.02250M -1.32400M
Change to netincome 5.20M -1.09100M 2.17M -1.40100M 0.67M
Capital expenditures 1.89M 1.79M 0.51M 0.79M 1.35M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1.61400M 0.61M 0.23M -0.50700M -0.06600M
Stock based compensation 4.39M 1.32M 0.27M - 0.33M
Other non cash items 2.78M 0.13M 0.01M - -0.02800M
Free cash flow -17.93700M -15.79800M -8.35400M - -8.66600M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AGL
ANGLE plc		 -1.225 51.04% 1.18 - - 18.87 0.88 5.81 -0.4917
IDHC
Integrated Diagnostics Holdings PLC		 -0.05 8.62% 0.53 0.20 12.89 3.33 6.89 3.22 8.79
HVO
hVIVO plc		 0.05 0.60% 8.40 7.05 18.32 0.89 1.01 0.69 2.93
ABDX
Abingdon Health Plc		 - -% 12.75 - 53.19 2.19 3.19 1.81 -0.2499
CLBX
CelLBxHealth plc		 0.12 6.94% 1.93 - - 7.05 1.50 6.07 -1.6211

Reports Covered

Stock Research & News

View All

Profile

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.

ANGLE plc

Surrey Research Park, Guildford, United Kingdom, GU2 7AF

Key Executives

Name Title Year Born
Mr. Andrew David William Newland Founder, CEO & Exec. Director 1962
Mr. Ian Francis Griffiths CFO, Fin. Director, Company Sec. & Exec. Director 1965
Mr. Martin Cooke Director of Operations & Regulatory Affairs 1969
Mr. Andrew John Holder Head of Investor Relations 1968
Mr. Paul Smith Chief Commercial Officer NA
Dr. Madeline Repollet Head of Clinical Laboratories NA
Ms. Anne-Sophie Pailhes-Jimenez Head of R&D - ANGLE Europe Ltd. NA
Mr. Michael O'Brien Bus. Devel. Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions